Neuphoria Therapeutics Inc. cash flow to debt ratio of -35.97M% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Neuphoria Therapeutics Inc.'s free cash flow has decreased 16.10K% from $77.23M last year to $-12.35B, signaling decreasing performance

Neuphoria Therapeutics Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Neuphoria Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.00 today, signaling strengthened financials

Neuphoria Therapeutics Inc. has a net cash position, so leverage is healthy.

Neuphoria Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Neuphoria Therapeutics Inc.'s profit margin was -2.36% last year and is -1.58K% this year, signaling decreasing performance

Neuphoria Therapeutics Inc.'s short-term assets of $21.07B exceed its short-term liabilities of $756.58M

Neuphoria Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Neuphoria Therapeutics Inc.'s return on equity of -77.03%, is lower than 15.00%, indicating bad performance

Neuphoria Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Neuphoria Therapeutics Inc. has insufficient public price history to evaluate earnings stability.

Neuphoria Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Neuphoria Therapeutics Inc. has negative free cash flow, indicating cash burn

Neuphoria Therapeutics Inc.'s yearly earnings has decreased 3.54K% since last year from $-369.63K to $-13.45M, signaling decreasing performance

Neuphoria Therapeutics Inc.'s yearly revenue has increased % since last year from $0.00 to $1.17B, signaling increasing performance

ROIC -49.41% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Neuphoria Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Neuphoria Therapeutics Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Neuphoria Therapeutics Inc. has insufficient public price history to evaluate ROE consistency.

Neuphoria Therapeutics Inc. is undervalued relative to its fair value price of 3.83K based on Base Cash Flow Valuation (DCF) model

Neuphoria Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Neuphoria Therapeutics Inc. is undervalued relative to its fair value price of 4.50K based on Base EBITDA Valuation model

Neuphoria Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Neuphoria Therapeutics Inc. has insufficient data to evaluate this check.

Neuphoria Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Neuphoria Therapeutics Inc. has a price-to-book ratio of 0.80x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Neuphoria Therapeutics Inc. has a price-to-sales ratio of 16.82x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue